Antibody-guided in vivo imaging of Aspergillus fumigatus lung infections during anti-fungal azole treatment
dc.contributor.author | Henneberg, S | |
dc.contributor.author | Hasenberg, A | |
dc.contributor.author | Maurer, A | |
dc.contributor.author | Neumann, F | |
dc.contributor.author | Bornemann, L | |
dc.contributor.author | Gonzales-Menendez, I | |
dc.contributor.author | Kraus, A | |
dc.contributor.author | Hasenberg, M | |
dc.contributor.author | Thornton, CR | |
dc.contributor.author | Pichler, BJ | |
dc.contributor.author | Gunzer, M | |
dc.contributor.author | Beziere, N | |
dc.date.accessioned | 2021-03-18T09:56:50Z | |
dc.date.issued | 2021-03-17 | |
dc.description.abstract | Invasive pulmonary aspergillosis (IPA) is a life-threatening lung disease of immunocompromised humans, caused by the opportunistic fungal pathogen Aspergillus fumigatus. Inadequacies in current diagnostic procedures mean that early diagnosis of the disease, critical to patient survival, remains a major clinical challenge, and is leading to the empiric use of antifungal drugs and emergence of azole resistance. A non-invasive procedure that allows both unambiguous detection of IPA, and its response to azole treatment, is therefore needed. Here, we show that a humanised Aspergillus-specific monoclonal antibody, dual labelled with a radionuclide and fluorophore, can be used in immunoPET/MRI in vivo and 3D light sheet fluorescence microscopy ex vivo to quantify early A. fumigatus lung infections and to monitor the efficacy of azole therapy. Our antibody-guided approach reveals that early drug intervention is critical to prevent complete invasion of the lungs by the fungus, and demonstrates the power of molecular imaging as a non-invasive procedure for tracking IPA in vivo. | en_GB |
dc.description.sponsorship | Ministry of Culture and Science of North Rhine-Westphalia | en_GB |
dc.description.sponsorship | Governing Mayor of Berlin including Science and Research | en_GB |
dc.description.sponsorship | Federal Ministry of Education and Research | en_GB |
dc.description.sponsorship | European Union FP7 | en_GB |
dc.description.sponsorship | Werner Siemens Foundation | en_GB |
dc.identifier.citation | Vol. 12, article 1707 | en_GB |
dc.identifier.doi | 10.1038/s41467-021-21965-z | |
dc.identifier.grantnumber | 602820 | en_GB |
dc.identifier.uri | http://hdl.handle.net/10871/125153 | |
dc.language.iso | en | en_GB |
dc.publisher | Nature Research | en_GB |
dc.rights | © The Author(s) 2021. Open Access. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ | en_GB |
dc.title | Antibody-guided in vivo imaging of Aspergillus fumigatus lung infections during anti-fungal azole treatment | en_GB |
dc.type | Article | en_GB |
dc.date.available | 2021-03-18T09:56:50Z | |
dc.identifier.issn | 2041-1723 | |
dc.description | This is the final version. Available on open access from Nature Research via the DOI in this record | en_GB |
dc.description | Data availability: Due to their large size, the raw imaging data that support the findings of this study are directly available from the corresponding authors upon reasonable request. Derived data have been compiled in the Source Data file provided with this paper. Any remaining data supporting the findings from this study are available from the corresponding author upon reasonable request. | en_GB |
dc.identifier.journal | Nature Communications | en_GB |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | en_GB |
dcterms.dateAccepted | 2021-02-16 | |
rioxxterms.version | VoR | en_GB |
rioxxterms.licenseref.startdate | 2021-03-17 | |
rioxxterms.type | Journal Article/Review | en_GB |
refterms.dateFCD | 2021-01-07T09:47:32Z | |
refterms.versionFCD | AM | |
refterms.dateFOA | 2021-03-18T09:56:54Z | |
refterms.panel | A | en_GB |
Files in this item
This item appears in the following Collection(s)
Except where otherwise noted, this item's licence is described as © The Author(s) 2021. Open Access. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/